Chemical industry in Puerto Rico

FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.

Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.

Orforglipron produced meaningful body‑weight and waist reductions across menopausal stages in ATTAIN‑1 and ATTAIN‑2, including women with type 2 diabetes.

Successor returns July 1 as EVP and assumes CFO duties Sept 1; outgoing CFO stays through Jan 2027 to aid transition. Successor has 30+ yrs finance leadership, ex‑CFO at Galderma, Shire, Sulzer.

Expands Puerto Rico biologics facility to boost U.S. production, deploy next‑gen technologies, support workforce development and construction jobs, and strengthen medicine supply‑chain resilience

Reese retires June 30, 2026. Effective June 1, leadership reshuffle: James Bradner named EVP R&D, AI & Data; Sean Bruich CTO; Murdo Gordon EVP Global Markets & Policy; Paul Burton remains CMO.

ACHIEVE-4: Foundayo non-inferior vs insulin glargine for MACE-4 (HR 0.84); improved A1C (-1.6 vs -1.0) and weight (-8.8% vs +1.7%) at 52 wks; 57% lower all-cause death; GI AEs; FDA filing planned.

RAINFOL‑01 D2 (n=40): common TEAEs—nausea 80%, fatigue 67.5%, anemia 55%, neutropenia 45%; serious TEAEs 15%; dose reductions 27.5%; no fatal TEAEs. Phase 3 RAINFOL‑04 ongoing.

BEHOLD-1 phase I: Mo-Rez (B7-H4 ADC) active across expression levels; manageable hematologic toxicity and nausea. 5.8 mg/kg recommended; five Phase III trials planned 2026

Phase 3 subcutaneous TEPEZZA met primary endpoint in moderate-to-severe TED: 76.7% proptosis response vs 19.6% placebo; mean −3.17 mm reduction; safety consistent; mild injection-site AEs